RPG Life Sciences Limited (RPGLIFE) - Net Assets

Latest as of September 2025: Rs5.54 Billion INR ≈ $59.91 Million USD

Based on the latest financial reports, RPG Life Sciences Limited (RPGLIFE) has net assets worth Rs5.54 Billion INR (≈ $59.91 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs7.06 Billion ≈ $76.32 Million USD) and total liabilities (Rs1.52 Billion ≈ $16.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of RPG Life Sciences Limited to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs5.54 Billion
% of Total Assets	78.5%
Annual Growth Rate	19.49%
5-Year Change	145.11%
10-Year Change	297.13%
Growth Volatility	74.28

RPG Life Sciences Limited - Net Assets Trend (2005–2025)

This chart illustrates how RPG Life Sciences Limited's net assets have evolved over time, based on quarterly financial data. Also explore RPG Life Sciences Limited asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for RPG Life Sciences Limited (2005–2025)

The table below shows the annual net assets of RPG Life Sciences Limited from 2005 to 2025. For live valuation and market cap data, see RPG Life Sciences Limited market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs5.31 Billion ≈ $57.37 Million	+41.53%
2024-03-31	Rs3.75 Billion ≈ $40.54 Million	+21.86%
2023-03-31	Rs3.08 Billion ≈ $33.27 Million	+20.26%
2022-03-31	Rs2.56 Billion ≈ $27.66 Million	+18.17%
2021-03-31	Rs2.16 Billion ≈ $23.41 Million	+22.59%
2020-03-31	Rs1.77 Billion ≈ $19.10 Million	+10.01%
2019-03-31	Rs1.60 Billion ≈ $17.36 Million	+3.72%
2018-03-31	Rs1.55 Billion ≈ $16.74 Million	+0.43%
2017-03-31	Rs1.54 Billion ≈ $16.66 Million	+15.34%
2016-03-31	Rs1.34 Billion ≈ $14.45 Million	+6.74%
2015-03-31	Rs1.25 Billion ≈ $13.54 Million	-0.48%
2014-03-31	Rs1.26 Billion ≈ $13.60 Million	+64.97%
2013-03-31	Rs762.30 Million ≈ $8.24 Million	+2.82%
2012-03-31	Rs741.40 Million ≈ $8.02 Million	-0.92%
2011-03-31	Rs748.31 Million ≈ $8.09 Million	+16.14%
2010-03-31	Rs644.31 Million ≈ $6.97 Million	+17.32%
2009-03-31	Rs549.21 Million ≈ $5.94 Million	+11.62%
2008-03-31	Rs492.02 Million ≈ $5.32 Million	-33.72%
2007-03-31	Rs742.36 Million ≈ $8.03 Million	+11.18%
2006-03-31	Rs667.72 Million ≈ $7.22 Million	+343.37%
2005-03-31	Rs150.60 Million ≈ $1.63 Million	--

Equity Component Analysis

This analysis shows how different components contribute to RPG Life Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 504778800000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs4.74 Billion	89.37%
Common Stock	Rs132.30 Million	2.49%
Other Comprehensive Income	Rs86.80 Million	1.64%
Other Components	Rs344.60 Million	6.50%
Total Equity	Rs5.31 Billion	100.00%

RPG Life Sciences Limited Competitors by Market Cap

The table below lists competitors of RPG Life Sciences Limited ranked by their market capitalization.

Company	Market Cap
Priority Technology Holdings Inc NASDAQ:PRTH	$410.60 Million
Guangdong Anjubao Digital Tech SHE:300155	$410.63 Million
Fastned B.V. AS:FAST	$410.84 Million
Ophir High Conviction Fund AU:OPH	$411.08 Million
Gladstone Land Corporation NASDAQ:LAND	$410.40 Million
Jiangsu Wanlin Modern Logistic SHG:603117	$410.35 Million
Taiwan Mask Corp TW:2338	$410.22 Million
Luxfer Holdings PLC NYSE:LXFR	$410.18 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in RPG Life Sciences Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,748,500,000 to 5,305,300,000, a change of 1,556,800,000 (41.5%).
Net income of 1,832,400,000 contributed positively to equity growth.
Dividend payments of 264,600,000 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs1.83 Billion	+34.54%
Dividends Paid	Rs264.60 Million	-4.99%
Other Changes	Rs-11.00 Million	-0.21%
Total Change	Rs-	41.53%

Book Value vs Market Value Analysis

This analysis compares RPG Life Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 7.15x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 189.41x to 7.15x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs12.12	Rs2295.00	x
2006-03-31	Rs53.67	Rs2295.00	x
2007-03-31	Rs51.67	Rs2295.00	x
2008-03-31	Rs34.62	Rs2295.00	x
2009-03-31	Rs38.19	Rs2295.00	x
2010-03-31	Rs39.03	Rs2295.00	x
2011-03-31	Rs45.26	Rs2295.00	x
2012-03-31	Rs44.83	Rs2295.00	x
2013-03-31	Rs46.10	Rs2295.00	x
2014-03-31	Rs76.05	Rs2295.00	x
2015-03-31	Rs75.69	Rs2295.00	x
2016-03-31	Rs80.79	Rs2295.00	x
2017-03-31	Rs93.16	Rs2295.00	x
2018-03-31	Rs93.57	Rs2295.00	x
2019-03-31	Rs97.04	Rs2295.00	x
2020-03-31	Rs106.76	Rs2295.00	x
2021-03-31	Rs130.87	Rs2295.00	x
2022-03-31	Rs154.65	Rs2295.00	x
2023-03-31	Rs185.98	Rs2295.00	x
2024-03-31	Rs226.65	Rs2295.00	x
2025-03-31	Rs320.79	Rs2295.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently RPG Life Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 34.54%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 28.04%
• Asset Turnover: 0.99x
• Equity Multiplier: 1.24x
Recent ROE (34.54%) is above the historical average (8.84%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	-144.22%	-17.29%	0.53x	15.62x	Rs-232.25 Million
2006	38.55%	17.84%	0.66x	3.29x	Rs190.64 Million
2007	10.83%	6.68%	0.59x	2.77x	Rs6.13 Million
2008	12.10%	4.66%	0.73x	3.57x	Rs10.33 Million
2009	12.03%	4.70%	0.84x	3.06x	Rs11.15 Million
2010	16.76%	6.75%	0.96x	2.60x	Rs43.53 Million
2011	16.99%	6.90%	0.96x	2.55x	Rs52.29 Million
2012	1.15%	0.44%	1.05x	2.47x	Rs-65.64 Million
2013	5.79%	1.99%	1.08x	2.70x	Rs-32.13 Million
2014	42.46%	22.69%	1.20x	1.56x	Rs408.24 Million
2015	0.80%	0.41%	1.23x	1.57x	Rs-115.16 Million
2016	8.70%	4.17%	1.36x	1.54x	Rs-17.39 Million
2017	13.28%	6.68%	1.24x	1.60x	Rs50.52 Million
2018	8.69%	3.99%	1.16x	1.88x	Rs-20.25 Million
2019	6.74%	3.34%	1.29x	1.57x	Rs-52.40 Million
2020	16.43%	7.86%	1.38x	1.51x	Rs113.53 Million
2021	18.48%	10.43%	1.26x	1.40x	Rs183.55 Million
2022	20.13%	11.78%	1.27x	1.35x	Rs259.03 Million
2023	21.99%	13.29%	1.21x	1.36x	Rs368.80 Million
2024	23.39%	15.18%	1.13x	1.37x	Rs501.75 Million
2025	34.54%	28.04%	0.99x	1.24x	Rs1.30 Billion

Industry Comparison

This section compares RPG Life Sciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $23,713,303,062
Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
RPG Life Sciences Limited (RPGLIFE)	Rs5.54 Billion	-144.22%	0.27x	$410.49 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$988.60 Million	6.59%	1.36x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$6.52 Billion	21.67%	1.42x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$1.16 Billion	12.69%	1.32x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.46 Billion	16.82%	0.29x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$8.73 Billion

About RPG Life Sciences Limited

NSE:RPGLIFE India Drug Manufacturers - Specialty & Generic

Market Cap

$410.49 Million

Rs37.96 Billion INR

Market Cap Rank

#13558 Global

#642 in India

Share Price

Rs2295.00

Change (1 day)

+13.03%

52-Week Range

Rs1744.00 - Rs2657.80

All Time High

Rs2828.55